Loading...
•
Dec 31, 2021
Cullinan Oncology Q4 2021 Earnings Report
Reported fourth quarter and full year 2021 financial results and provided a corporate update.
Key Takeaways
Cullinan Oncology reported its fourth quarter and full year 2021 financial results. Clinical trials for CLN-619 and CLN-049 were initiated, and an HPK1 degrader collaboration with Mount Sinai was established. The company finished the year with over $430 million in cash and investments.
Reported compelling data from the ongoing Phase 1/2a trial of CLN-081.
FDA granted CLN-081 Breakthrough Therapy Designation.
Initiated clinical trials for CLN-619 and CLN-049.
Expanded pipeline with an HPK1 degrader collaboration with the Icahn School of Medicine at Mount Sinai.
Cullinan Oncology
Cullinan Oncology
Forward Guidance
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
Positive Outlook
- Cullinan’s beliefs and expectations regarding our preclinical and clinical development plans
- clinical trial designs
- clinical and therapeutic potential
- strategy of our product candidates
- our ability to evaluate strategic opportunities to accelerate development timelines
Challenges Ahead
- uncertainty regarding the timing and results of regulatory submissions
- success of our clinical trials and preclinical studies
- risks related to our ability to protect and maintain our intellectual property position
- risks related to manufacturing, supply, and distribution of our product candidates
- risks related to the impact of COVID-19 affecting countries or regions in which we have operations or do business, including potential negative impacts on our employees, customers, supply chain and production as well as global economies and financial markets